(MedPage Today) -- Patients with rheumatoid arthritis treated with the interleukin-6 receptor blocker tocilizumab (Actemra) experienced the expected increases in lipids, but also had favorable alterations in certain types of lipid particles, researchers found. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment